Multiple Myeloma Clinical Trial
Study of Oral IXAZOMIB in Combination With Lenalidomide and Dexamethasone in Participants With Newly Diagnosed Multiple Myeloma
Summary
The purpose of this study is to determine the safety, tolerability, maximum tolerated dose (MTD), and recommended phase 2 dose (RP2D) in phase 1 and to determine the combined response rate of clinical response CR and very good partial response (VGPR) in phase 2 of oral (PO) ixazomib administered twice-weekly in combination with lenalidomide and low-dose dexamethasone in a 21-day cycle in participants with newly diagnosed multiple myeloma (NDDM).
Full Description
The drug being tested in this study is called ixazomib. Ixazomib was tested to slow disease progression and improve overall survival in participants who have newly diagnosed multiple myeloma (NDMM). This study looked at the safety, tolerability and response in participants when administered in combination with lenalidomide and low-dose dexamethasone.
The study enrolled 64 patients. Participants were assigned to one of the 3 treatment groups:
Phase 1 Ixazomib 3 mg
Phase 1 Ixazomib 3.7 mg
Phase 2 Ixazomib 3 mg
All participants were administered with Ixazomib capsules, orally, twice-weekly on Days 1, 4, 8, and 11 along with lenalidomide capsules, orally, once daily on Days 1-14 and dexamethasone, capsules, orally, once daily on Days 1, 2, 4, 5, 8, 9, 11, and 12 for up to 16 cycles in the absence of disease progression or unacceptable toxicity as induction therapy during Phase 1. Participants with stable or responding disease continued receiving ixazomib capsules, orally, twice weekly on Days 1, 4, 8, and 11 in 21-day treatment cycles as maintenance therapy until progressive disease or unacceptable toxicity.
This multi-center trial conducted in the United States. The overall time to participate in this study was 2037 days. Participants will make multiple visits to the clinic, and a final visit after 30 days after last dose of study drug for a follow-up assessment.
Eligibility Criteria
Inclusion Criteria:
Male or female patients 18 years or older
Symptomatic multiple myeloma or asymptomatic myeloma with myeloma-related organ damage diagnosed according to standard criteria
Measurable disease as specified in study protocol
Hematologic, liver, and renal function as specified in the study protocol.
Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
Female patients who are post menopausal, surgically sterile, or agree to practice 2 effective methods of contraception or agree to abstain from heterosexual intercourse; must also adhere to the guidelines of the lenalidomide pregnancy prevention program
Male patients who agree to practice effective barrier contraception or agree to abstain from heterosexual intercourse AND must adhere to the guidelines of the lenalidomide pregnancy prevention program
Must be able to take concurrent aspirin 325 mg daily
Voluntary written consent
Exclusion Criteria
Peripheral neuropathy that is greater or equal to Grade 2
Female patients who are lactating or pregnant
Major surgery or radiotherapy within 14 days before the first dose of study drug
Uncontrolled infection requiring systematic antibiotics within 14 days before the first dose of study drug
Diarrhea (> Grade 1)
Prior systemic therapy for multiple myeloma, including investigational drugs (prior treatment with corticosteroids or localized radiation therapy dose not disqualify the patient)
Systemic treatment with strong inhibitors of CYP1A2, strong inhibitors of CYP3A, or strong CYP3A inducers, or use of Ginkgo biloba or St. John's wort within 14 days before the first dose of study treatment
Central nervous system involvement
Diagnosis of smoldering multiple myeloma, Waldenstrom's macroglobulinemia, POEMS syndrome, plasma cell leukemia, primary amyloidosis, myelodysplastic syndrome, or myeloproliferative syndrome
Evidence of current uncontrolled cardiovascular conditions
Prior or concurrent deep vein thrombosis or pulmonary embolism
Known human immunodeficiency virus (HIV) positive, hepatitis B surface antigen-positive status, or known or suspected active hepatitis C infection
Serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to the protocol
Known allergy to any of the study medications
Known gastrointestinal condition or procedure that could interfere with swallowing or the oral absorption, or tolerance of IXAZOMIB
Diagnosed or treated for another malignancy within 2 years before the first dose or previously diagnosed with another malignancy and have any evidence of residual disease with the exception of nonmelanoma skin cancer or any completely resected carcinoma in situ
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 19 Locations for this study
Berkeley California, 94704, United States
Duarte California, 91010, United States
Stanford California, 94305, United States
Tampa Florida, 33612, United States
Chicago Illinois, 60637, United States
Rockville Maryland, 20850, United States
Boston Massachusetts, 02115, United States
Ann Arbor Michigan, 48109, United States
Lansing Michigan, 48910, United States
Hackensack New Jersey, 07601, United States
New York New York, 10021, United States
New York New York, 31406, United States
Durham North Carolina, 27705, United States
Columbus Ohio, 43210, United States
Toledo Ohio, 43623, United States
Portland Oregon, 97239, United States
Nashville Tennessee, 37203, United States
Dallas Texas, 75246, United States
Fairfax Virginia, 22031, United States
Fairfax Virginia, 22031, United States
How clear is this clinincal trial information?

Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.